| Literature DB >> 28468307 |
Ariana Picu1,2, Laura Petcu3,4, Simona Ştefan5, Manuela Mitu6, Daniela Lixandru7, Constantin Ionescu-Tîrgovişte8,9, Grațiela Grădișteanu Pîrcălăbioru10,11, Felicia Ciulu-Costinescu12, Maria-Viorica Bubulica13, Mariana Carmen Chifiriuc14,15.
Abstract
Type 2 diabetes mellitus (T2DM) is strongly associated with obesity. The adipose tissue secretes bioactive adipokines leading to low grade inflammation, amplified by oxidative stress, which promotes the formation of advanced glycation end products and eventually leads to dyslipidemia and vascular complications. The aim of this study was to correlate anthropometric, biochemical and oxidative stress parameters in newly diagnosed (ND) T2DM patients and to investigate the role of oxidative stress in T2DM associated with obesity. A group of 115 ND- T2DM patients was compared to a group of 32 healthy subjects in terms of clinical, anthropometric, biochemical and oxidative stress parameters. ND-T2DM patients had significantly lower adiponectin, glutathione (GSH) and gluthatione peroxidase (GPx) and elevated insulin, proinsulin, HOMA-IR index, proinsulin/insulin (P/I) and proinsulin/adiponectin (P/A) ratio, fructosamine, and total oxidant status (TOS). The total body fat mass was positively correlated with total oxidant status (TOS). Positive correlations were found between TOS and glycated hemoglobin (HbA1c), and between TOS and glycaemia. Negative correlations were identified between: GPx and glycaemia, GPx and HbA1c, and also between GSH and fructosamine. The total antioxidant status was negatively correlated with the respiratory burst. The identified correlations suggest the existence of a complex interplay between diabetes, obesity and oxidative stress.Entities:
Keywords: inflammation; obesity; oxidative stress; reactive oxygen species; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2017 PMID: 28468307 PMCID: PMC6154306 DOI: 10.3390/molecules22050714
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The values for anthropometric and clinical parameters for control group and T2DM patients.
| Anthropometrical and Clinical Parameters | Control Group (CG) | ND-T2DM Patients (ND-T2DM) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Males N = 15 | Females N = 17 | Total N = 32 | Males N = 60 | Females N = 55 | Total N = 115 | CG vs. ND-T2DM | Males CG vs. Males T2DM | Females CG vs. Females T2DM | |
| Age (years) | 48.40 ± 12.70 | 48.41 ± 17.32 | 48.41 ± 15.10 | 59.23 ± 9.57 | 57.34 ± 10.18 | 58.33 ± 9.87 | |||
| Weight (kg) | 81.32 ± 13.20 | 68.65 ± 20.26 | 74.33 ± 18.35 | 91.63 ± 13.37 | 83.63 ± 18.47 | 87.88 ± 16.39 | |||
| Waist circumference (WC) (cm) | 97.75 ± 14.68 | 88.75 ± 16.64 | 91.75 ± 15.96 | 106.52 ± 7.48 | 102.37 ± 11.47 | 104.55 ± 9.77 | NS | NS | |
| Body mass index (BMI) (kg/m2) | 26.70 ± 3.23 | 25.96 ± 5.82 | 26.33 ± 4.78 | 30.50 ± 3.85 | 32.44 ± 6.06 | 31.43 ± 5.11 | |||
| Fat mass (%) | 23.53 ± 6.39 | 33.82 ± 9.01 | 29.41 ± 9.42 | 30.56 ± 5.26 | 41.96 ± 5.43 | 36.20 ± 7.82 | |||
| Visceral fat level (%) | 9.75 ± 3.95 | 6.75 ± 4.26 | 8.04 ± 4.33 | 15.76 ± 4.19 | 11.02 ± 2.78 | 13.42 ± 4.27 | |||
| SBP (mmHg) | 120 ± 8.16 | 124.1 ± 10.83 | 122 ± 9.57 | 128 ± 8.65 | 129 ± 13.68 | 128 ± 11.35 | NS | ||
| DBP (mmHg) | 67.30 ± 10.12 | 72.50 ± 8.66 | 69.80 ± 9.63 | 74.64 ± 9.30 | 75.09 ± 9.08 | 74.87 ± 9.15 | NS | NS | |
Data are expressed as mean ± SD; SBP–systolic blood pressure; DBP–diastolic blood pressure; NS = not significant.
The biochemical characteristics of T2DM patients versus healthy subjects.
| Biochemical Parameters | Control Group (Healthy Subjects) (CG) | ND-T2DM Patients (ND-T2DM) | |
|---|---|---|---|
| Glycemia a jeun (mg/dL) | 96.20 ± 6.91 | 172.53 ± 74.29 | |
| HbA1c (%) | 5.62 ± 0.26 | 7.74 ± 2.03 | |
| Fructosamine (µmol/L) | 408.04 ± 82.39 | 572.32 ± 311.18 | |
| Creatinine (mg/dL) | 0.84 ± 0.17 | 0.85 ± 0.18 | NS |
| Serum Urea (mg/dL) | 29.78 ± 6.64 | 34.60 ± 9.53 | |
| Serum total cholesterol (mg/dL) | 211.20 ± 46.50 | 215.33 ± 52.72 | NS |
| Serum HDLc (mg/dL) | 51.55 ± 13.21 | 44.63 ± 12.31 | |
| Triglycerides (mg/dL) | 120.08 ± 45.24 | 180.36 ± 101.67 | |
| Serum LDLc (mg/dL) | 135.48 ± 47.53 | 136.09 ± 47.40 | NS |
| Total Chol./HDLc | 4.46 ± 1.64 | 5.12 ± 1.63 | |
| Tg./HDLc (Atherogenic Index) | 2.66 ± 1.78 | 4.67 ± 3.37 | |
| AST (U/I) | 22.99 ± 10.71 | 23.84 ± 12.95 | NS |
| ALT (U/I) | 25.20 ± 17.85 | 30.13 ± 15.35 | NS |
| Uric Acid (mg/dL) | 5.28 ± 1.99 | 5.99 ± 1.73 | NS |
| GGT(U/I) | 39.50 ± 9.15 | 46.27 ± 6.36 | NS |
| Albumin (g/dL) | 4.33 ± 0.27 | 4.31 ± 0.21 | NS |
| Total Serum Proteins (g/dL) | 7.00 ± 0.41 | 6.96 ± 0.46 | NS |
Data are expressed as mean ± SD; NS = not significant; AST—aspartate aminotransferase; ALT–alanine aminotransferase; GGT–gamma glutamyltransferase.
The values of parameters relevant to the assessment of pancreatic cell function, adipose tissue and oxidative status.
| Parameters | Control Group (Healthy Subjects) (CG) | ND-T2DM Patients (ND-T2DM) | |
|---|---|---|---|
| Insulin (µUI/mL) | 9.20 ± 4.96 | 13.74 ± 10.68 | |
| HOMA-IR Index (%) | 2.20 ± 1.23 | 5.74 ± 4.39 | |
| HOMA-BETA Index (%) | 102.87 ± 52.23 | 63.92 ± 6.97 | |
| Proinsulin (pmol/L) | 1.25 ± 0.49 | 6.69 ± 0.82 | |
| Proinsulin/Insulin (P/I) | 0.10 ± 0.005 | 0.53 ± 0.06 | |
| Proinsulin/Adiponectin (P/A) | 0.25 ± 0.07 | 1.81 ± 0.39 | |
| C-Peptide (ng/mL) | 3.34 ± 2.19 | 4.66 ± 2.92 | |
| Leptin (ng/mL) | 13.98 ± 3.19 | 17.50 ± 16.18 | NS |
| Adiponectin (µg/mL) | 13.08 ± 10.30 | 8.10 ± 7.57 | |
| SuperoxideDismutase (SOD) (U/g Hb) | 99.72 ± 22.95 | 95.72 ± 19.92 | NS |
Data are expressed as mean ± SD; NS = not significant; HOMA-IR: Homeostasis Model Assessment for Insulin Resistance; HOMA-BETA: Homeostasis Model for Beta cell function; PMA: phorbol 12-myristate 13-acetate; LM: 5-amino-2,3-dihydro-1,4-phthalazinedione; LG: bis-N-methylacridinium nitrate; OZ: opsonized zymosan.
Figure 1Total oxidant status (TOS) (A) total antioxidant status (TAS) (B) in patients with ND-T2DM versus control group (CG).
Figure 2Circulating levels of glutathione peroxidase (GPx) (A) and glutathione (GSH) (B) in patients with ND-T2DM versus control group (CG).
Figure 3Respiratory burst (PMA and LG) (A) and (OZ and LG) (B) in patients with ND-T2DM versus control group (CG).